Are you Dr. Josephson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 64 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
921 Terry Ave
Seattle, WA 98104Phone+1 206-292-6570Fax+1 206-520-5620
Summary
- Dr. Neil Josephson, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington, Oregon, and Illinois. He is affiliated with UW Medicine/Harborview Medical Center and UW Medicine/University of Washington Medical Center.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1994 - 1998
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1988 - 1991
Columbia University Vagelos College of Physicians and SurgeonsClass of 1988
Certifications & Licensure
OR State Medical License 1991 - Present
WA State Medical License 1994 - 2025
IL State Medical License 1988 - 1993
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A Start of enrollment: 2012 Jul 01
Publications & Presentations
PubMed
- 17 citationsPhenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon ResonanceKenneth B. Lewis, Richard J. Hughes, Melinda S. Epstein, Neil C. Josephson, Christine L. Kempton
Plos One. 2013-05-08 - 392 citationsBrentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s LymphomaJoseph M. Connors, Wojciech Jurczak, David J. Straus, Stephen M. Ansell, Won Kim
The New England Journal of Medicine. 2017-12-10 - 168 citationsBrentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura
Blood. 2018-07-05
Press Mentions
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract CancerApril 28th, 2022- Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast CancerDecember 8th, 2021
- Zymeworks Announces Abstract for Zanidatamab in First-Line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual CongressSeptember 12th, 2021
- Join now to see all
Grant Support
- Gene Therapy For The Treatment Of CamtNational Heart, Lung, And Blood Institute2005–2009
- Gene Transfer Into Stem Cells By Foamy Virus VectorsNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2005
- Gene Transfer Into Stem Cells By Foamy Virus VectorsNational Institute Of Diabetes And Digestive And Kidney Diseases2001–2003
- Overexpression Of HOXB4 In CAT Hematopoietic CellNational Heart, Lung, And Blood Institute1997–1998
